Working Core Outcome Set Aims to Improve Cutaneous Lupus Erythematosus Clinical Trials
Researchers developed a working core outcome set with the objective of improving clinical studies in cutaneous lupus erythematosus.
Researchers developed a working core outcome set with the objective of improving clinical studies in cutaneous lupus erythematosus.
In a letter to the editor, authors reported the case of chilblain lupus-like cutaneous reaction that fulfilled the criteria for systemic lupus erythematosus in a patient who received treatment with immune checkpoint inhibitors for oropharyngeal cancer.
Researchers identified the transcriptional profile and composition of immune cells in the peripheral blood of patients with rheumatoid arthritis, systemic lupus erythematosus, and primary Sjögren syndrome.
The association between psoriasis and lympho-hematological malignancies in 25 observational cohort studies is evaluated.
The differences in presentation of frontal fibrosing alopecia (FFA) in black women and white women was investigated.
Randomized, controlled trials in pediatric inflammatory rheumatic diseases (PiRDs) of patients who underwent bDMARDs and JAK inhibitors are reviewed.
According to data from a press release, which were later presented at the EULAR 2021 Virtual Congress, “Anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures…in patients with moderate to severe SLE.”
The efficacy of BIIBO59 in patients with cutaneous lupus erythematosus with and without concomitant systemic lupus erythematosus during 16 weeks was evaluated.
Researchers studied the effect of income on quality of life in patients with cutaneous lupus erythematosus.
Skin microvascular function was assessed via laser speckle contrast analysis (LASCA) in patients with SLE, with and without cardiovascular disease and risk factors.